Isolation and identification of SARS-CoV-2 antibodies from COVID-19 patient samples

Isolation and identification of SARS-CoV-2 antibodies from COVID-19 patient samples

<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causing agent for COVID-19, has led to over 7 million deaths since it was first detected in Wuhan, China in December 2019. Antibodies induced by both vaccination and infection are crucial for the immune protection ag...

Bibliografiset tiedot
Päätekijä:	Liu, C
Muut tekijät:	Screaton, GR
Aineistotyyppi:	Opinnäyte
Kieli:	English
Julkaistu:	2024
Aiheet:	Immunology

Samankaltaisia teoksia

SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
Tekijä: Alba Escalera, et al.
Julkaistu: (2024-03-01)

Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection
Tekijä: Xiao-Lin Jiang, et al.
Julkaistu: (2024-07-01)

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2
Tekijä: Cyril Planchais, et al.
Julkaistu: (2024-07-01)

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
Tekijä: Jeewandara, C, et al.
Julkaistu: (2021)

Cross-reactive immunity to SARS-CoV-2 and related coronaviruses
Tekijä: Jay, C
Julkaistu: (2023)

Nonhuman primate antigenic cartography of SARS-CoV-2
Tekijä: Annika Rössler, et al.
Julkaistu: (2025-01-01)

Studies on immunoreceptor activation and SARS-CoV-2 RBD/ACE2 interactions
Tekijä: Barton, MI
Julkaistu: (2022)

Anti-SARS-CoV-2 antibodies in a nasal spray efficiently block viral transmission between ferrets
Tekijä: Kiira Gildemann, et al.
Julkaistu: (2024-07-01)

SARS-CoV-2 produces a microRNA CoV2-miR-O8 in patients with COVID-19 infection
Tekijä: Elise J. Tucker, et al.
Julkaistu: (2024-01-01)

Epitopes recognition of SARS-CoV-2 nucleocapsid RNA binding domain by human monoclonal antibodies
Tekijä: Youngchang Kim, et al.
Julkaistu: (2024-02-01)

Development of human monoclonal antibodies against SARS-CoV-2
Tekijä: Wong, Joel Xu En
Julkaistu: (2021)

SARS-CoV-2 infection elucidates features of pregnancy-specific immunity
Tekijä: Dong Sun Oh, et al.
Julkaistu: (2024-11-01)

Multivariate analyses and machine learning link sex and age with antibody responses to SARS-CoV-2 and vaccination
Tekijä: Miroslava Cuperlovic-Culf, et al.
Julkaistu: (2024-08-01)

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
Tekijä: Tetsuya Inoue, et al.
Julkaistu: (2024-04-01)

Increasing Sporadic Covid-19 Cases:Should We Heed Airborne Transmission Of SARS-CoV-2?
Tekijä: Ahmad Mahfuz, Gazali
Julkaistu: (2021)

An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spike
Tekijä: Banghui Liu, et al.
Julkaistu: (2024-06-01)

Characterisation of HBV and SARS-CoV-2 spike specific T cells and their association with viral control
Tekijä: Liu, G
Julkaistu: (2023)

Functional diversification of innate and inflammatory immune responses mediated by antibody fragment crystallizable activities against SARS-CoV-2
Tekijä: Martina Severa, et al.
Julkaistu: (2024-05-01)

SARS-CoV-2 vaccine development and challenges
Tekijä: Duan Fugang, et al.
Julkaistu: (2021-03-01)

Elucidating factors of heterogeneous immune response to SARS-CoV-2 and human immunodeficiency virus
Tekijä: Lim, N
Julkaistu: (2024)

Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1
Tekijä: Zhou Tong, et al.
Julkaistu: (2024-06-01)

SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity
Tekijä: Elizabeth J. Martinez, et al.
Julkaistu: (2024-10-01)

Variant- and vaccination-specific alternative splicing profiles in SARS-CoV-2 infections
Tekijä: Sung-Gwon Lee, et al.
Julkaistu: (2024-03-01)

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
Tekijä: Cara W. Chao, et al.
Julkaistu: (2024-12-01)

SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model
Tekijä: Sarah E. Cummings, et al.
Julkaistu: (2024-01-01)

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
Tekijä: Carter, Brandon, et al.
Julkaistu: (2023)

tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains
Tekijä: Daniel Ivanusic, et al.
Julkaistu: (2024-03-01)

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1
Tekijä: Alexander Muik, et al.
Julkaistu: (2024-08-01)

Convergence of SARS-CoV-2 spike antibody levels to a population immune setpointResearch in context
Tekijä: Eric J. Nilles, et al.
Julkaistu: (2024-10-01)

Characterising the T cell responses to SARS-CoV-2 including variants of concern induced by natural infection and vaccines
Tekijä: Adele, S
Julkaistu: (2024)

Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters
Tekijä: Rajesh Rajaiah, et al.
Julkaistu: (2024-08-01)

Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion
Tekijä: Lu Zhang, et al.
Julkaistu: (2024-06-01)

Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection
Tekijä: Mohamed I.M. Ahmed, et al.
Julkaistu: (2024-06-01)

Immune imprinting of SARS-CoV-2 responses: changing first immune impressions
Tekijä: J. Torresi, et al.
Julkaistu: (2024-04-01)

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine
Tekijä: Masayuki Aboshi, et al.
Julkaistu: (2024-02-01)

A systems biology approach to define SARS-CoV-2 correlates of protection in non-human primates
Tekijä: Brady, C
Julkaistu: (2024)

The alarmin IL-33 exacerbates pulmonary inflammation and immune dysfunction in SARS-CoV-2 infection
Tekijä: Hui Wang, et al.
Julkaistu: (2024-06-01)

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Tekijä: Willett, BJ, et al.
Julkaistu: (2022)

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Tekijä: Hirsch, C, et al.
Julkaistu: (2021)

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
Tekijä: Kreuzberger, N, et al.
Julkaistu: (2021)